Dexter Walcott, MD
Allergy & Immunology · Jackson, MSNPI 1457321325
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,657 of the $153,749 with a category attached, or 79.8%. Sanofi accounts for 60.4% of it on its own, with 35 other manufacturers making up the rest.
Across 837 payments — averaging $183.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$93K
- Regeneron Healthcare Solutions, Inc.$44K
- Covis Pharma GmbH$5K
- GSK$2K
- AstraZeneca$2K
- CSL Behring$2K
- plus $6K from 30 others
What the payments were for
- Consulting fees$7,8175%
- Speaking & faculty fees$122,65780%
- Travel & lodging$5,4214%
- Food & beverage$17,56111%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 97 | $92,837 |
| Regeneron Healthcare Solutions, Inc. | 105 | $43,823 |
| Covis Pharma GmbH | 3 | $5,279 |
| GSK | 172 | $2,482 |
| AstraZeneca | 96 | $2,017 |
| CSL Behring | 78 | $1,799 |
| Pfizer | 44 | $852 |
| Novartis | 33 | $613 |
| Genentech USA, Inc. | 32 | $608 |
| Amgen | 28 | $516 |
| Grifols USA, LLC | 24 | $437 |
| Octapharma USA, Inc. | 21 | $397 |
| LEO Pharma Inc. | 9 | $204 |
| Optinose US, Inc. | 10 | $181 |
| Pharming Healthcare, Inc. | 8 | $177 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $167 |
| Biocryst US Sales Co., LLC | 7 | $158 |
| Boehringer Ingelheim | 8 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $154 |
| Sanofi-aventis U.S. LLC | 2 | $142 |
| Kaleo, Inc. | 9 | $129 |
| AbbVie | 6 | $105 |
| Blueprint Medicines Corporation | 4 | $86 |
| Galderma Laboratories, L.p. | 3 | $72 |
| Shire North American Group Inc | 3 | $52 |
| Lilly USA, LLC | 2 | $44 |
| Merck | 3 | $44 |
| Incyte Corporation | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Ionis Pharmaceuticals, Inc. | 2 | $34 |
| Greer Laboratories, Inc. | 1 | $23 |
| Dermavant Sciences, Inc. | 1 | $23 |
| Gebauer Company | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Biocryst Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,749 in reported general payments places this provider in the 85th percentile of 28 allergy & immunology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 42 | $158,498 |
| Dupixent PenDupilumab | 41 | $148,152 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $130,662 |
| NucalaMepolizumab | 29 | $111,696 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $58,566 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $57,891 |
| XolairOmalizumab | 17 | $33,422 |
| DuleraMometasone/Formoterol | 28 | $15,882 |
| Azelastine Hcl | 539 | $14,583 |
| Ipratropium Bromide | 300 | $11,410 |
| Epinephrine | 39 | $8,828 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,766 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,436 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 199 | $7,334 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,482 | $315,001363 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,017 | $67,332102 claims |
| MerckDulera | $44 | $15,88228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 allergy & immunology providers in Mississippi.
Other allergy & immunology in Jackson
- Todd AdkinsJackson$226K
- Daniel VenarskeJackson$156K
- Chelle WilhelmJackson$61K
- Joshua PhillipsJackson$20K
- Claire RosenblattJackson$11K
- James HaltomJackson$11K
- Gailen MarshallJackson$4K
- Sheryll VincentJackson$3K
- Matthew ElliottJackson$862
- Stephen KempJackson$68
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.